Optimistic Growth Prospects for Gossamer Bio Amid Strategic Advances and Study Alignments

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Gossamer Bio (GOSS – Research Report) on May 15 and set a price target of $6.00.

Joseph Schwartz has given his Buy rating due to a combination of factors that indicate potential growth and opportunity for Gossamer Bio. The company’s recent earnings call highlighted that the baseline characteristics in the PROSERA study align well with the target demographic, despite a slight delay in the expected topline data to February 2026. This alignment is crucial as it suggests that the study is targeting more severe patients, which is consistent with positive signals observed in previous studies.
Furthermore, despite the increasing adoption of Merck’s Winrevair, there is still a perceived opportunity for Gossamer’s seralutinib to secure a place in the treatment landscape for pulmonary arterial hypertension. Additionally, Gossamer is making strides in addressing pulmonary hypertension associated with interstitial lung disease, with plans for a pivotal trial. These strategic moves and the potential for positive outcomes in their studies contribute to Schwartz’s optimistic outlook and the Buy rating for Gossamer Bio.

In another report released on May 16, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $0.00 price target.

GOSS’s price has also changed dramatically for the past six months – from $0.740 to $1.050, which is a 41.89% increase.